• Mashup Score: 2
    23andMe Granted New FDA Clearance to Report Additional BRCA Variants - 8 month(s) ago

    510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these additional variants occur more often in people of African American and Hispanic/Latino descent 23andMe also granted an FDA Predetermined Change Control Plan, allowing the company to update its BRCA report with additional variants without a pre-market submission, provided those variants meet the same rigor

    Source: finance.yahoo.com
    Categories: Latest Headlines, Oncologists2
    Tweet Tweets with this article
    • Profile photo of genperisi
      genperisi

      RT @westr: @23andMe Granted New FDA Clearance to Report Additional #BRCA Variants https://t.co/WW3V8kX4Zf via @YahooFinance "will allow #…

  • Mashup Score: 3
    Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting - 9 month(s) ago

    AbstractGermline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS <36 months), and (iii) long-term responders (OS >36 months). Patient-derived xenografts (PDX) were generated from 25 patients with glBRCA PDAC at different clinical time points. Response to platinum/PARP inhibition in vivo and ex vivo culture (EVOC) correlated with clinical response. We deciphered the mechanisms of resistance in glBRCA PDAC and identified homologous recombination (HR) proficiency and secondary mutations restoring partial functionality as the most dominant resistant mechanism. Yet, a subset of HR-deficient (HRD) patients demonstrated clinical resistance. Their tumors displayed basal-like molecular s

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CD_AACR
      CD_AACR

      #ICYMI— Spectrum of Response to Platinum and #PARP Inhibitors in Germline #BRCA–Associated #PancreaticCancer in the Clinical and Preclinical Setting, by @ChaniStossel, Maria Raitses-Gurevich Talia Golan et al. https://t.co/dKqtorhfSw @sheba_medical @TelAvivUni https://t.co/c1x9hjKqug

  • Mashup Score: 4
    Applying genetic principles to treatment of BRCA-mutant cancers - The Institute of Cancer Research, London - 11 month(s) ago

    Photo: Luke Henry, the ICRWe demonstrated that drugs called PARP inhibitors could be particularly effective in BRCA-mutant cancers and, with The Royal Marsden NHS Foundation Trust, helped run clinical trials leading to the first PARP inhibitor being licensed in ovarian cancer. The PARP inhibitor story began back in the mid-1990s, when a team of researchers at The Institute of Cancer Research –…

    Source: www.icr.ac.uk
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ICR_London
      ICR_London

      🔬🧬We previously applied genetic principles to discover a novel strategy for #Cancer treatment for patients with #BRCA 1/2 mutations. Read more about the ICR’s role in the science that underpins the olaparib discovery: https://t.co/8W5SOcdjIx

  • Mashup Score: 31
    Germline Genetic Testing After Cancer Diagnosis - 11 month(s) ago

    This observational study describes the prevalence of germline genetic testing in California and Georgia between 2013 and 2019 among patients diagnosed with cancer.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Aiims1742
      Aiims1742

      Among 1.3 million patients Dxed with cancer between 2013 & 2019, ~93,000 (6.8%) underwent germline testing through 2021. The rate of germline mutation testing in #PancreaticCancer - where universal testing is a @NCCN & @ASCO guideline - was a mere 5.6%! 🤦🏽‍♂️ https://t.co/Dmk4lhqNvL https://t.co/62sjBXTSpK

    • Profile photo of EricTopol
      EricTopol

      For patients with cancer, assessment for the potential of familial (germline) pathogenic mutations (like #BRCA) is recommended, but infrequently performed. When done, it's very informative https://t.co/enx6QiJ97I @JAMA_current https://t.co/0Pv3UJNORC

  • Mashup Score: 0
    Applying genetic principles to treatment of BRCA-mutant cancers - The Institute of Cancer Research, London - 11 month(s) ago

    Photo: Luke Henry, the ICRWe demonstrated that drugs called PARP inhibitors could be particularly effective in BRCA-mutant cancers and, with The Royal Marsden NHS Foundation Trust, helped run clinical trials leading to the first PARP inhibitor being licensed in ovarian cancer. The PARP inhibitor story began back in the mid-1990s, when a team of researchers at The Institute of Cancer Research –…

    Source: www.icr.ac.uk
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ICR_London
      ICR_London

      These crucial trials led to major changes in the treatment of #OvarianCancer, by using, for the first time, new targeted drugs to treat patients with mutations in their #BRCA genes. https://t.co/8W5SOcdjIx https://t.co/2pXOZmEQ7u

Load More